Heidelberg, Germany, January 26, 2004 - The Max Planck Institute for Medical Research, Heidelberg, and Axaron Bioscience AG have inked a service contract covering the application of Axaron's Axaminer technology, a method enabling gene expression profiling at the cellular level for bioinformatic evaluation.
Axaron's Axaminer technology will be used at the Heidelberg MPI in conjunction with a project aimed at analyzing the molecular processes of glutamate-mediated signal transduction. As Professor Peter H. Seeburg, Director of the Department of Molecular Neurobiology at the Heidelberg MPI explains: "We are hoping these investigations will lead to a better understanding of neurological diseases such as stroke, for example."
Axaminer, an Axaron service for cell type-specific transcription profiling of cells isolated from complex tissues and organs, comprises four integrated modules: specific cell labeling, automated cell isolation using laser microdissection, the isolation and amplification of tiny amounts of RNA, as well as subsequent transcription profiling. The technology is offered either as a full service or tailored solution and allows observations of molecular processes at the cellular level that would not be possible using existing analytical methods.
Axaron Bioscience AG
Im Neuenheimer Feld 515
Tel.: 06221 454-705
Fax: 06221 454-776
Axaron Bioscience AG is a Heidelberg-based biotechnology company which pioneers innovative therapies for neurodegenerative diseases such as stroke or Parkinson's. The company capitalizes on its uniquely integrated functional genomics and proteomics technology platform and its world-leading network of expert partners in the CNS field. Axaminer is based on Axaron's proprietary technology and enables gene expression profiling at a cellular level. The Axaminer technology comprises four integrated modules offered as a full service or tailor-made solution to pharmaceutical companies. For further information please visit www.axaron.com